In psoriasis, therapeutic strategies targeting IL‐23 and IL‐17 have shown superior efficacy over TNF inhibitors, while the former may be less beneficial in inflammatory bowel disease [48, 49, 50]. Here, IL17A is linked to inflammatory bowel disease.